MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway

被引:49
作者
Zhai, Zhen [1 ]
Mu, Tianlong [1 ,2 ]
Zhao, Lina [1 ]
Li, Yiliang [1 ]
Zhu, Dongsheng [1 ]
Pan, Yanshu [3 ]
机构
[1] Beijing Univ Chinese Med, Breast Dept, Dongfang Hosp, 6 Bldg, Beijing 100078, Peoples R China
[2] Beijing Univ Chinese Med, Pathol Dept, Dongfang Hostipal, Beijing, Peoples R China
[3] Beijing Univ Chinese Med, Period Ctr, Beijing, Peoples R China
关键词
Breast cancer; miR-181-5p; NDRG2; proliferation; invasion; glycolysis; INHIBITS CELL-PROLIFERATION; GENE; 2; NDRG2; TUMOR-SUPPRESSOR; MIGRATION; GLUTAMINOLYSIS;
D O I
10.1080/21655979.2021.2006974
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Dysregulation of microRNAs (miRNAs) is associated with the occurrence and development of breast cancer. In this research, we explored the involvement of miR-181a-5p in the progression of breast cancer and investigated potential molecular mechanisms. Firstly, the miR-181a-5p and N-myc downstream-regulated gene (NDRG) 2 expression was detected by real-time quantitative polymerase chain reaction. Cellular processes were assessed using Cell Counting Kit 8, Bromodeoxyuridine, colony formation and transwell assays. HK2, PKM2 and LDHA activities were assessed by ELISA. The combination between miR-181a-5p was assessed by dual-luciferase reporter assay and RNA pull-down assay. The results indicated that miR-181a-5p levels were upregulated and NDRG2 levels were downregulated in breast cancer, leading to poor prognosis. Silencing of miR-181a-5p inhibited cell proliferation, invasion, glycolysis, and xenograft tumor growth, while enhanced miR-181a-5p got the opposite results. Furthermore, NDRG2 acts as a target of miR-181a-5p. Knockout of NDRG2 facilitated biological behaviors and meanwhile enhanced phosphorylation (p)-PTEN and p-AKT levels. Rescue experiments showed that restoring NDRG2 abolished the effects caused by miR-181a-5p in breast cancer cells. In conclusion, miR-181a-5p facilitated tumor progression through NDRG2-induced activation of PTEN/AKT signaling pathway of breast cancer, suggesting that focusing on miR-181a-5p may provide new insight for breast cancer therapy.
引用
收藏
页码:83 / 95
页数:13
相关论文
共 40 条
[1]  
Akram M, 2017, BIOL RES, V50
[2]   Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer [J].
Alexandrova, Elena ;
Lamberti, Jessica ;
Saggese, Pasquale ;
Pecoraro, Giovanni ;
Memoli, Domenico ;
Valeria, Mirici Cappa ;
Ravo, Maria ;
Iorio, Roberta ;
Tarallo, Roberta ;
Rizzo, Francesca ;
Collina, Francesca ;
Cantile, Monica ;
Di Bonito, Maurizio ;
Botti, Gerardo ;
Nassa, Giovanni ;
Weisz, Alessandro ;
Giurato, Giorgio .
CELLS, 2020, 9 (04)
[3]   Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer [J].
Benedetti, Rosaria ;
Papulino, Chiara ;
Sgueglia, Giulia ;
Chianese, Ugo ;
De Marchi, Tommaso ;
Iovino, Francesco ;
Rotili, Dante ;
Mai, Antonello ;
Nimeus, Emma ;
Dell'Aversana, Carmela ;
Altucci, Lucia .
CANCERS, 2021, 13 (03) :1-19
[4]   The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications [J].
Carnero, Amancio ;
Blanco-Aparicio, Carmen ;
Renner, Oliver ;
Link, Wolfgang ;
Leal, Juan F. M. .
CURRENT CANCER DRUG TARGETS, 2008, 8 (03) :187-198
[5]   PTEN: Tumor Suppressor and Metabolic Regulator [J].
Chen, Chien-Yu ;
Chen, Jingyu ;
He, Lina ;
Stiles, Bangyan L. .
FRONTIERS IN ENDOCRINOLOGY, 2018, 9
[6]   Potential role of NDRG2 in reprogramming cancer metabolism and epithelial-to-mesenchymal transition [J].
Chen, Xiang-Liu ;
Lei, Lan ;
Hong, Lian-Lian ;
Ling, Zhi-Qiang .
HISTOLOGY AND HISTOPATHOLOGY, 2018, 33 (07) :655-663
[7]   Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling [J].
Ding, Xiang ;
Xu, Xu ;
He, Xue-Feng ;
Yuan, Ye ;
Chen, Chuang ;
Shen, Xin-Yu ;
Su, Sai ;
Chen, Zhang ;
Xu, Song-Tao ;
Huang, Yu-Hua .
BIOENGINEERED, 2021, 12 (01) :803-814
[8]  
Fisusi Funmilola A., 2019, Pharmaceutical Nanotechnology, V7, P3, DOI 10.2174/2211738507666190122111224
[9]   NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma [J].
Furuta, Hiroshi ;
Kondo, Yuudai ;
Nakahata, Shingo ;
Hamasaki, Makoto ;
Sakoda, Sumio ;
Morishita, Kazuhiro .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 391 (04) :1785-1791
[10]   Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response [J].
Gill, Kheshwant S. ;
Fernandes, Philana ;
O'Donovan, Tracey R. ;
McKenna, Sharon L. ;
Doddakula, Kishore K. ;
Power, Derek G. ;
Soden, Declan M. ;
Forde, Patrick F. .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2016, 1866 (01) :87-105